AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Prior research indicated that inhibiting the PI3K/AKT pathway enhances the sensitivity of CML LSCs to treatment, hence reinforcing the assertion that HULC plays a role in imatinib resistance via elevating phosphorylation within the PI3K/AKT pathway [119].